Reuters: The drugmakers purchased Idenix Pharmaceuticals Inc. for $3.85 billion to boost its hepatitis C drugs portfolio.
Reuters: The drugmakers purchased Idenix Pharmaceuticals Inc. for $3.85 billion to boost its hepatitis C drugs portfolio.
Cambridge, Massachusetts-based Idenix, which focuses on the treatment of human viral diseases, has three drugs in development to treat hepatitis C.
An estimated 3.2 million people in the United States are living with chronic hepatitis C infection, with most being unaware of the infection and showing no symptoms, according to the U.S. Centers for Disease Control and Prevention.
Read more here.
